romoszumab

Romosozumab is a medication used to treat osteoporosis in postmenopausal women who are at high risk for fracture. It is administered as a subcutaneous injection. Romosozumab works by inhibiting sclerostin, a protein that plays a role in bone formation and resorption. By blocking sclerostin, romosozumab increases bone formation and decreases bone resorption, leading to improved bone mineral density and reduced fracture risk.

The efficacy and safety of romosozumab have been evaluated in clinical trials. These studies have shown that romosozumab significantly reduces the risk of vertebral, non-vertebral, and clinical fractures compared to placebo or other osteoporosis treatments. However, a potential increased risk of cardiovascular events, including myocardial infarction and stroke, has been observed in patients treated with romosozumab. Consequently, its use is generally reserved for individuals who have not responded to or cannot tolerate other osteoporosis therapies.

The recommended dosage of romosozumab is 210 mg administered subcutaneously once a month for a total of 12 months. It is typically given in conjunction with calcium and vitamin D supplementation. Patients receiving romosozumab should be monitored for any signs or symptoms of cardiovascular events. The long-term effects and optimal duration of treatment are still areas of ongoing research.